论文部分内容阅读
目的评价紫杉醇脂质体周疗联合卡铂治疗老年晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法 41例老年晚期NSCLC患者采用紫杉醇脂质体80mg/m2,第1、8、15天;卡铂300mg/m2,第1天,每4周重复一次,对完成两个周期以上化疗的患者评价疗效及不良反应。结果 41例患者中,客观缓解率(ORR)为41.5%,中位无进展生存时间(PFS)为5.3个月,中位总生存时间(OS)为9.9个月,1年生存率为34.1%。其中IIIB期患者和IV期患者的ORR分别为65.0%和19.0%,中位PFS分别为7.8个月和4.1个月,中位OS分别为14.1个月和9.0个月,差异均有统计学意义(P<0.05)。主要不良反应为I～II级白细胞减少、血小板减少和贫血。非血液学不良反应较温和,耐受性良好。结论紫杉醇脂质体每周疗法联合卡铂治疗老年晚期NSCLC患者安全有效,值得临床进一步推广应用。
Objective To evaluate the efficacy and safety of paclitaxel liposome combined with carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Forty-one elderly patients with advanced NSCLC were treated with paclitaxel liposome 80mg / m2 on days 1, 8 and 15 and carboplatin 300 mg / m2 on day 1 and every 4 weeks. Patients who completed more than two cycles of chemotherapy were evaluated Efficacy and adverse reactions. Results Among the 41 patients, the objective response rate (ORR) was 41.5%, the median progression-free survival time (PFS) was 5.3 months, the median overall survival time (OS) was 9.9 months and the 1-year survival rate was 34.1% . The ORs of stage IIIB patients and stage IV patients were 65.0% and 19.0%, respectively. The median PFS was 7.8 months and 4.1 months respectively. The median OS was 14.1 months and 9.0 months respectively, with statistical significance (P <0.05). The main adverse reactions were grade I-II leukopenia, thrombocytopenia and anemia. Non-hematologic adverse reactions were mild and well tolerated. Conclusion paclitaxel liposome weekly combined with carboplatin in the treatment of elderly patients with advanced NSCLC safe and effective, it is worth further clinical application.